SCHEMBL3765778

SCHEMBL3765778

[CH2]C(C(C)=O)N1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.38
DPP7 Q9UHL4 1/20 0.35
ALDH1A1 P00352 6/20 0.34
MAPT P10636 2/20 0.34
GAA P10253 2/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MAOB P27338 1/20 0.33
CHRM1 P11229 1/20 0.32
HPGD P15428 1/20 0.32
CHRNB2 P17787 4/20 0.32
SLC6A2 P23975 4/20 0.32
CHRNB4 P30926 4/20 0.32
CHRNA3 P32297 4/20 0.32
CHRNA4 P43681 4/20 0.32
SLC6A3 Q01959 4/20 0.32
CHRNA1 P02708 3/20 0.32
CHRNG P07510 3/20 0.32
CHRNB1 P11230 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706557 0.75 DPP7 (0.42) FDPSDPP7ALDH1A1MAPTGAA
SCHEMBL27915742 0.75 FDPS (0.41) FDPSDPP7ALDH1A1MAPTGAA
SCHEMBL14850491 0.73 MAOB (0.44) FDPSDPP7ALDH1A1GAAMEN1
SCHEMBL12462690 0.73 MAOB (0.44) FDPSDPP7ALDH1A1GAAMEN1
SCHEMBL14159627 0.73 FDPS (0.39) FDPSDPP7ALDH1A1MAPTGAA
SCHEMBL17348912 0.73 MAOB (0.44) FDPSDPP7ALDH1A1GAAMEN1
SCHEMBL10666808 0.73 FDPS (0.35) FDPSDPP7ALDH1A1GAA
SCHEMBL29086465 0.71 HPGD (0.38) FDPSALDH1A1MAPTLMNAMEN1
SCHEMBL6103198 0.71 TSHR (0.41) FDPSDPP7ALDH1A1MAPTGAA
SCHEMBL13255632 0.70 ATM (0.42) FDPSALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA FDPS 854/4885DPP7 421/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.